FDA puts added emphasis on amyloid in update on Alzheimer's R&D guidance
The FDA on Monday released newly-revised guidance on early Alzheimer’s disease drug development, including a section that boosts the case for using amyloid reduction as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
